{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-150830","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.330766+00:00","generated_at":"2026-06-25T15:19:50.539583+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026","bullets":["Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.","Net loss $12.9M vs $34.2M Q4 2021; R&D expense $24.5M, G&A $8.1M.","CLN-081 co-development deal with Taiho: $275M upfront, up to $130M milestones, 50/50 US profit share.","CLN-081 granted Breakthrough Therapy Designation; 41% confirmed ORR at 100mg BID; ASCO oral June 2022.","IND filings for CLN-617 and CLN-978 on track for H1 2023; CLN-049 and CLN-619 Phase 1 dosing ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-150830","json":"https://secwatch.observer/filing/0001193125-22-150830.json","markdown":"https://secwatch.observer/filing/0001193125-22-150830.md","text":"https://secwatch.observer/filing/0001193125-22-150830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/0001193125-22-150830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/d696900d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:19:50.539583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}